MERIT RESEARCH JOURNALS
www.meritresearchjournals.org

Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 4(10) pp. xxx-xxx, October, 2016
Available online http://www.meritresearchjournals.org/mms/index.htm
Copyright © 2016 Merit Research Journals

Original Research Article

Obestatin and Copeptin Levels in Egyptian Polycystic Ovary Patients and their Relation to Obesity, Insulin Resistance and Cardiovascular Risk

Abeer I. Abd El-Fattah[1], Adel A. Elboghdady[2], Mahmoud M. Kamel[3*] and Elfeshawy S. Mohamed[4]

[1]Department of Biochemistry, Faculty of Pharmacy (Girls), Al-Azhar University

[2]Department of Obstetrics and Gynecology, Faculty of Medicine (Boys), Al-Azhar University

[3]Department of Clinical pathology, National Cancer Institute, Cairo University

[4]Department of Radiology, Faculty of Medicine (Boys), Al-Azhar University.

***Correspondence Author's E-mail: mm.kamel@yahoo.com**
Telephone: +201018470990

Abstract

The aim of this study is to investigate the correlations between the serum levels of obestatin and copeptin, carotid artery intima-media thickness (CIMT), and brachial artery flow mediated dilatation (FMD) in obese and non-obese women with PCOS. Secondly to investigate their relationship with each other and with clinical, metabolic, hormonal parameters and cardiovascular risk factors. We analyzed 54 patients with PCOS and 20 age-matched healthy women as controls. PCOS patients were divided into two groups based on body mass index (BMI): obese group (BMI > 30 kg/m^2, n = 28) and non-obese group (BMI < 30 kg/m^2, n = 26). Serum copeptin and obestatin levels, insulin homeostasis model assessment for insulin resistance (HOMA-IR), CIMT and brachial artery FMD were determined and compared among the groups. Women with PCOS, especially obese ones, had higher triglycerides, HOMA-IR, hirsutism score, total testosterone, CRP, systolic and diastolic blood pressure, and waist-to-hip ratio (WHR), and lower HDL. Serum obestatin levels were significantly lower in obese PCOS group than non-obese and control. While Serum copeptin levels were significantly higher in obese PCOS group than non-obese and control. Brachial artery FMD was lower in the PCOS groups than control. Obestatin was positively correlated with cardiovascular risk factor (FMD), whereas copeptin was negatively correlated with FMD. Obestatin and copeptin may provide useful information regarding future cardiovascular risk in PCOS patients as obestatin was negatively correlated and copeptin was positively correlated with cardiovascular risk factor (FMD).

Keywords: Cardiovascular Risk, Copeptin, Insulin resistance, Obesity, Obestatin, Polycystic ovary

INTRODUCTION

The polycystic ovary syndrome (PCOS) is a hyperandrogenic disorder associated with chronic oligo-anovulation, polycystic ovarian morphology, hyperandrogenism, menstrual disturbance, anovulation, infertility and obesity (Azziz et al., 2006; Pasquali et al., 2006), and also associated with an increased number of cardiovascular risk factors (Orio et al., 2004), and early atherosclerosis (Kelly et al., 2001; Kelly et al., 2002). Hyperinsulinism and insulin resistance are frequent findings in PCOS patients, and these traits have cause-consequence relationships with low-grade chronic inflammation (Escobar-Morreale et al., 2005), and increased cardiovascular disease risk (Legro, 2003).

Obestatin is peptide hormone secreted by the cells of the stomach and small intestine of several mammals including humans. Although obestatin and ghrelin are both

encoded by the same gene and derived from the precursor protein proghrelin, obestatin behaves as a physiological opponent to ghrelin in inhibiting food intake, body weight gain, and gastric mptying (Zhang et al., 2005).

Arginine vasopressin, which is also named antidiuretic hormone, is released from the posterior pituitary gland in conditions of chronic psychosocial stress via inducing the hypothalamic–pituitary–adrenal (HPA) axis along with corticotropin-releasing hormone (Saleem et al., 2009). Bjorntorp and Rosmond (1999) suggest that stress-mediated activation of the HPA axis may have a role in the pathogenesis of insulin resistance and metabolic syndrome.

Copeptin is C-terminal portion of the precursor of Arginine vasopressin (AVP). Copeptin is considered to be a reliable and clinically useful surrogate marker for AVP. In healthy populations and in patients with various cardiovascular diseases, there is a significant positive association between copeptin and AVP levels (Holmes et al., 2003; Morgenthaler et al., 2006).

However, the association between copeptin, obestatin levels and patients with PCOS remains unknown. The present study was, therefore, undertaken to investigate the correlations between both serum levels of obestatin, copeptin, in PCOS patients and to evaluate their relationship with obesity, insulin resistance as well as cardiovascular disease risk and other metabolic and anthropometric variables.

SUBJECTS AND METHODS

Study population

In this prospective study, we analyzed 54 patients with PCOS and 20 age-matched healthy women as controls. The patients with PCOS were divided into two groups based on body mass index (BMI): obese group (BMI > 30 kg/m^2, n = 28) or non-obese group (BMI < 30 kg/m^2, n = 26). Patients were recruited from the outpatient clinics of the Department of Obstetrics and Gynecology, El-Hussein and Sayed Galal Hospitals, Al-Azhar University, in the period between January and August 2015.

The study protocol was in accordance with the Helsinki Committee requirements and was approved by the Ethics Committee of Faculty of Pharmacy (Girls), Al-Azhar University. All patients gave written consent before the study. The diagnosis of PCOS was made based on the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine (ESHRE/ASRM) criteria (Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), 2004).

A pelvic ultrasound examination was performed on the same day as blood sampling. All women were examined by the same physician. Patients who had taken oral contraceptive agents, antilipidemic or antihypertensive drugs, glucocorticoids, antiandrogens, insulin sensitizers, anticoagulants, or antiplatelet agents at least 3 months before the study were excluded. Hirsutism was determined by the Ferriman–Gallwey score (Ferriman and Gallwey, 1961). Waist-to-hip ratio (WHR), which indicated visceral fat accumulation, was calculated. The body mass index (BMI) was calculated as weight (in kilograms)/height squared (meters squared). The BMI, WHR, and hirsutism scores were assessed by the same physician.

Laboratory Investigations

Sampling

A sample of 10 ml venous blood was collected from each subject after an overnight fasting. The venous blood sample was divided into two test tubes. 1ml was added to a mixture of potassium oxalate and sodium fluoride (for plasma fasting glucose estimation (FBG) by oxidase/ peroxidase kit) according to the principle of Caraway and Watts (1987) and the remaining 9 ml were allowed to clot at room temperature then centrifuged at 1000 rpm for 15 minutes. Serum was separated and divided into aliquots then frozen at -20 ^{o}C till the time of assay. The serum samples were used to estimate the following parameters:

Specific laboratory tests

1- Determination of serum obestatin was measured by a solid phase enzyme linked immunosorbent assay (ELISA) technique. The kit supplied by ALPCO DIAGNOSTICS, Catalog Number: 48-OBEHU-E01, inc:, according to the principle of Zhang et al. (2005)
2- Determination of serum copeptin was determined with a sandwich ELISA technique using Phoenix Pharmaceuticals, Inc: USA, according to the principle of Porstmann and Kiessig (1992).
3- Determination of Total testosterone was measured by the solid phase enzyme immunoassay (ELISA Kit), according to the principle of Marcus and Durnford, (1985).
4- Determination of serum CRP was measured using the Monobind Inc: USA (Ridker et al., 1998).
5- Determination of serum Insulin: by a solid phase enzyme linked immunosorbent assay (ELISA) Kit (Andersen et al., 1993)

Routine laboratory investigations

They include estimation of serum Triglycerides: by enzymatic colorimetric kit (Fossati and Principe, 1982). Total cholesterol: by enzymatic colorimetric kit (Allain et al., 1974). HDL-cholesterol: by phosphotungstate precipitation kit (Lopes-Virella et al., 1977). LDL- choles-

Table 1. Clinical characteristics and biochemical data of all studied groups.

	Obese		Non obese		Control		LSD		
	Mean	**±SD**	**Mean**	**±SD**	**Mean**	**±SD**	**I vs. II**	**I vs. III**	**II vs. III**
Age years	24.03	2.61	23.23	2.45	23.75	2.77	0.235	0.706	0.491
DM	5 (16.67%)		4 (13.33%)		0 (0.0%)		0.485	0.097	0.092
CVD	7 (23.33%)		5 (16.67%)		0 (0.0%)		0.522	0.063	0.070
BMI Kg/m2	37.25	1.16	23.69	1.18	23.54	1.34	<0.001	<0.001	0.670
WHR	0.76	0.07	0.69	0.05	0.69	0.06	<0.001	<0.001	0.962
Hirsutism score	6.27	1.80	5.63	2.14	2.10	1.02	0.174	<0.001	<0.001
SBP mmHg	132.67	17.99	122.67	12.85	99.50	9.99	0.009	<0.001	<0.001
DBP mmHg	81.00	10.94	73.33	8.84	63.50	8.75	0.003	<0.001	<0.001
Total Testosterone ng/dl	1.25	0.94	1.12	0.90	0.12	0.05	0.042	<0.001	<0.001
Total Chol. mg/dl	168.44	18.70	164.70	13.03	159.44	15.81	0.369	0.056	0.260
LDL mg/dl	84.86	11.62	83.05	11.18	79.73	12.46	0.550	0.132	0.329
HDL mg/dl	35.33	3.91	49.79	4.20	47.72	5.39	<0.001	<0.001	0.109
TG mg/dl	241.17	40.97	159.12	4.72	158.77	4.25	<0.001	<0.001	0.962
CRP	6.47	3.64	4.40	2.70	1.46	0.99	0.027	<0.001	0.003
FBG mmol/L	4.58	0.77	3.21	1.27	2.91	0.74	<0.001	<0.001	0.298
Insulin IU/ml	8.55	0.88	6.91	0.96	6.54	0.91	<0.001	<0.001	0.171
HOMA-IR	1.72	0.32	0.97	0.43	0.86	0.21	<0.001	<0.001	0.245

terol was estimated by the equation of Friedewald et al. (1972) with triglyceride < 393 mg/dl.

LDL-Cholesterol=Total cholesterol - (triglyceride/5 + HDL-Cholesterol).

Insulin resistance was estimated by Homeostasis Model Assessment [25].

HOMA-IR = [fasting insulin (μU/ml) X fasting glucose (mmol/L)]/22.5

III-Measurement of carotid artery intima-media thickness and brachial artery flow-mediated vasodilation

The determination of endothelial dysfunction was performed according to Celermajer et al. [26]. Measurements were made by a single observer using an ATL 5000 ultrasound system (Advanced Technology Laboratories Inc., Bothell, Wash., USA) with a 12-MHz probe.

The maximum flow-mediated dilatation (FMD) diameters were calculated as the average of the 3 consecutive maximum diameter measurements. The FMD was then calculated as the percent change in diameter compared with baseline resting diameters. All patients were blindly examined by 1 experienced operator (Levy et al., 1988).

Carotid intima-media thickness (CIMT) is measured at 1 cm proximal to the bifurcation on each side as previously described. Carotid atherosclerosis is described as having a CIMT greater than 0.8 mm and/or a carotid plaque with protrusion into the vascular lumen 1-1.3 mm (Pignoli et al., 1986).

Statistical Method

Data were analyzed using Statistical Program for Social Science (SPSS) version 20.0. Quantitative data were expressed as mean± standard deviation (SD). Qualitative data were expressed as frequency and percentage. A one-way analysis of variance (ANOVA) when comparing between more than two means. Post Hoc test was used for multiple comparisons between different variables. Chi-square (X2) test of significance was used in order to compare proportions between two qualitative parameters. Pearson's correlation coefficient (r) test was used for correlating data. Probability (P-value) <0.05 was considered significant

RESULTS

The distribution frequency % of history of diabetes mellitus(DM) and CVD in PCOS patients showed no difference between obese and non-obese ones.

BMI and WHR were significantly increased in obese PCOS patients when compared to both control and non-obese ones. Hitsutism score was significantly increased in PCOS patients when compared to controls. SBP, DBP, total testosterone and CRP were higher in the PCOS patients especially obese group than in the control group.

Regarding lipid profile, TG was significantly increased in obese PCOS patients when compared to both control and non-obese ones. While HDL-c was significantly decreased in obese PCOS patients when compared to both control and non-obese ones (Table 1).

In relation to insulin resistance assessment, it was found that FBG, serum insulin and HOMA-IR were significantly increased in obese PCOS patients when compared to both control and non-obese ones (Table 1).

Serum obestatin levels were significantly decreased in obese PCOS patients when compared to both control and non-obese ones. While serum copeptin levels were significantly increased in obese PCOS patients when compared to both control and non-obese ones. FMD%

Table 2. Comparison between all studied groups according to serum obestatin and copeptin levels, CIMT, and FMD.

	Obese		Non-obese		Control		LSD		
	Mean	±SD	Mean	±SD	Mean	±SD	I vs. II	I vs. III	II vs. III
CIMT mm	0.30	0.01	0.30	0.01	0.30	0.01	0.468	0.132	0.387
Obestatin Pg/ml	2.25	1.03	4.74	4.38	6.97	5.31	0.014	<0.001	0.047
Copeptinn g/ml	6.65	2.29	5.22	2.12	3.35	1.31	0.016	<0.001	0.002
FMD %	15.13	0.95	14.86	0.91	18.03	3.61	0.601	<0.001	<0.001

Table 3. Correlation between copeptin, obestatin, CIMT, FMD and all studied parameters in PCOS patients.

	CIMT mm		Obestatin Pg/ml		Copeptinn g/ml		FMD %	
	R	p-value	R	p-value	r	p-value	R	p-value
CIMT mm			-0.057	0.766	-0.064	0.738	-0.011	0.954
Obestatin Pg/ml	-0.057	0.766			-0.073	0.702	0.033	0.864
Copeptinn g/ml	-0.064	0.738	-0.073	0.702			0.072	0.706
FMD %	-0.011	0.954	0.517	0.014	-0.463	0.025		
Age years	0.285	0.127	-0.317	0.088	-0.009	0.963	-0.241	0.200
BMI Kg/m2	0.181	0.338	-0.368	0.004	0.472	0.020	0.024	0.899
WHR	-0.135	0.478	-0.334	0.036	0.336	0.042	0.055	0.772
Hirsutism score	0.054	0.779	0.086	0.652	0.479	0.020	-0.116	0.543
SBP mmHg	0.001	0.995	-0.217	0.250	0.268	0.047	-0.128	0.501
DBP mmHg	0.026	0.892	-0.287	0.124	0.332	0.028	-0.119	0.532
Total Testosterone ng/dl	-0.094	0.622	0.257	0.170	0.617	0.013	-0.219	0.246
Total Chol. mg/dl	0.064	0.738	-0.488	0.025	0.650	<0.001	0.079	0.677
LDL mg/dl	0.097	0.609	0.156	0.410	0.500	0.005	0.030	0.876
HDL mg/dl	0.052	0.785	0.124	0.516	-0.806	<0.001	-0.081	0.671
TG mg/dl	-0.017	0.927	0.307	0.099	0.390	0.033	0.176	0.353
CRP	-0.024	0.899	-0.432	0.021	0.543	0.007	0.388	0.034
FBG mmol/L	-0.036	0.851	-0.252	0.052	0.526	0.003	-0.218	0.246
Insulin IU/ml	0.047	0.805	0.381-	0.003	0.294	0.115	0.016	0.932
HOMA-IR	0.018	0.924	-0.321	0.012	0.661	<0.001	-0.159	0.401

was significantly decreased in PCOS patients when compared to controls. CIMT showed no difference between all groups (Table 2).

Obestatin was negatively correlated with BMI, WHR, total cholesterol, CRP, serum insulin and HOMA-IR in PCOS patients.

On the other hand, there was a significant positive correlation between obestatin levels and FMD in PCOS patients.

Regarding copeptin, there was a significant positive correlation between copeptin and total cholesterol, triglycerides, LDL, blood pressure, BMI, WHR, hirsutism score, total testosterone, CRP and HOMA-IR in PCOS patients (Table 3).

Additionally, there was a significant negative correlation between copeptin levels and cardiovascular risk marker (FMD)and HDL-c in PCOS patients (Table 3).

DISCUSSION

Polycystic ovaries (PCO) are the morphological ovarian phenotype in women with the polycystic ovary syndrome (PCOS). Several studies have been performed to attempt to determine the prevalence of PCO as detected by ultrasound alone in the general population, and have found prevalence rates in the order of 17–33% (Renato et al., 2011).

It is the first study to our knowledge, which correlates the serum levels of both obestatin and copeptin with obesity, insulin resistance and cardiovascular risk in polycystic ovary in Egypt, through the estimation of the serum levels of obestatin and copeptin, carotid artery intima-media thickness, brachial artery flow mediated dilatation and other metabolic and hormonal parameters in obese and non-obese women with PCOS and age-matched healthy controls.

In the present study, the obese women with PCOS have a significantly higher level of triglycerides, HOMA-IR, total testosterone, hirsutism score, CRP, blood pressure and WHR values and lower LDH levels when compared to control and non-obese ones.

In accordance with these results, Giallauria et al. (2008) reported that PCOS women represent an intriguing biological model illustrating the relationship between hormonal pattern and cardiovascular risk profile, presenting a cluster of cardiovascular features, such as obesity, insulin resistance, hypertension, impaired cardiopulmonary functional capacity, auto-nomic dysfunction and low-grade chronic inflammation

(Giallauria et al., 2008). Several studies suggested that PCOS is frequently associated with various patterns of dyslipidemia including low high density lipoprotein cholesterol (HDL-C), high levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol (LDL-C) (Wild et al., 1985; Talbott et al., 1998; Ehrmann et al., 2006).

Obestatin was first described as a bioactive peptide encoded by the same gene as ghrelin, playing a role in reducing food intake, body weight gain, and gastric emptying and suppressing intestinal motility and regulation of hormone secretion (Tang et al., 2008).

In the current study, the serum levels of obestatin were significantly lower in PCOS group, especially in obese ones than control group. This finding was in accordance with other studies in humans have shown that plasma obestatin is significantly lower in obese subjects as compared to lean controls, indicating a role for obestatin in long-term body weight regulation (Ren et al., 2009). Additionally, concluded that obestatin and ghrelin in normal weight groups were significantly higher than they were in obese groups. All these findings potentiate the hypothesis that the increased obesity rates in PCOS may be attributed to low obestatin levels. Therefore, low obestatin levels may predict the underlying factor of obesity in PCOS patients.

Regarding the possibility of using obestatin for cardiovascular risk assessment in PCOS, the present study showed that there was a significant positive correlation between obestatin levels and cardiovascular risk markers (FMD) in PCOS patients. This in accordance with Taskin et al. (2015) who found that obestatin is correlated with FMD and may be used for cardiovascular risk assessment in PCOS.

In the current study, obestatin was also negatively correlated with CRP in PCOS patients. This result came in agreement with Taskin et al. (2015) who suggested that low obestatin levels may reflect low grade chronic inflammation in PCOS.

PCOS is associated with oxidative stress, namely increased production of free radicals followed by decreased serum antioxidant levels and antioxidant enzyme activity. It is thought that metabolic dysfunction like obesity, hyperinsulinemia, and dyslipidemia might be responsible for PCOS-associated oxidative stress (Macut et al., 2013).

Since antioxidant effects of obestatin have been recently approved (Koc et al., 2014). Therefore, we would expect an association between obestatin and dyslipidemia and insulin resistance. In our study, obestatin was also negatively correlated with total cholesterol and HOMA-IR in PCOS patients. This finding potentiates the hypothesis that decreased obestatin levels in PCOS, as an antioxidant, may contribute to increased oxidative stress in PCOS patients (Taskin et al., 2015).

Copeptin is a marker of vasopressin level that reflects the individual stress level because of its hemodynamic and osmoregulatory effects. In the present study, the serum levels of copeptin were significantly higher in PCOS group, especially in obese ones than control group. This finding was in accordance with Karbek et al. (2014) and Taskin et al. (2015)

In relation to the association between copeptin levels, insulin resistance and metabolic syndrome, the present study demonstrated that there was a significant positive correlation between copeptin and total cholesterol, triglycerides, LDL, blood pressure, BMI and HOMA-IR in PCOS patients. These findings came in agreement with several studies which assumed that stress mediated hypothalamic pituitary adrenal axis activation, regulated by copeptin, was found to have a role in the pathophysiology of insulin resistance and metabolic syndrome (Saleem et al., 2009; Enhornling et al., 2013). Additionally, Tenderenda-Banasiuk et al. (2014) reported that higher serum copeptin levels are associated with systolic and diastolic blood pressure and several components of metabolic syndrome including obesity, elevated triglycerides.

Since copeptin is a neurohormon (NH) of the Arginine vasopressin AVP system (Voors et al., 2009), we would expect the possibility of using copeptin for cardiovascular risk assessment in PCOS, the present study showed that there was a significant negative correlation between copeptin levels and cardiovascular risk markers (FMD) in PCOS patients. This in accordance with recent studies showed that copeptin was elevated in acute myocardial infarction (AMI) and resulted in better diagnostic performance when assessed in combination with cardiac troponin, particularly during the first hour after onset of symptoms (Reichlin et al., 2009; Keller et al., 2010; Gu et al., 2011) and Taskin et al. (2015) observed PCOS patients had higher copeptin levels and these elevated copeptin levels are associated with increased cardiovascular risk in PCOS.

These previous studies revealed that copeptin is not only a marker of cardiovascular diseases, but of other conditions as well. Potential links of copeptin with DM, metabolic syndrome (MetS) and microalbuminuria have drawn particular interest in the recent years. The AVP system has also been suggested to contribute to insulin resistance and DM potentially through a variety of mechanisms including stimulation of glucagon and ACTH secretion and glycogenolysis (Enhörning et al., 2010). Therefore, copeptin, as a surrogate marker of this system, might also be associated with disrupted glucose homeostasis: a recent study demonstrated that increased copeptin levels were found to be associated with insulin resistance ($p < 0.001$) in a large population of 4742 subjects (cross-sectionally) (Enhörning et al., 2010). Consistent with this, copeptin was also reported to have a cross-sectional association with metabolic syndrome in a large population of subjects (Enhörning et al., 2011; Enhörning et al., 2013).

CONCLUSION

Obestatin and copeptin may be regarded as promising markers of cardiometabolic risk as well as additional guide in the early identification of PCOS patients at risk for cardiovascular disease. The present study concluded also that insulin resistance and obesity are associated with both serum obestatin and copeptin levels, hence they appeared to have an important role in metabolic response and subsequent development of atherosclerosis in insulin resistant, obese, hyperandrogenemic PCOS patients.

Conflicts of Interest

All Authors disclose no conflict of interest.

REFERENCES

Allain CA, Poon LS, Chan CS, Richmond W, Fu PC (1974). Enzymatic determination of total serum cholesterol. Clin. Chem., 20(4): 470 – 475.

Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder MF (1993). Enzyme immunoassay for intact human insulin in serum or plasma. Clin. Chem., 38: 578 – 582.

Azziz R, Carmina E, Dewailly, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ,Taylor AE, Witchel SF (2006). Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. Journal of Clinical Endocrinology and Metabolism.; 91:4237–4245. [PubMed: 16940456].

Bjorntorp P, Rosmond R (1999). Hypothalamic origin of the metabolic syndrome X. Ann NY Acad Sci; 892:297–307.

Caraway, W.T. and Watts, N.B. (1987). Carbohydrates in: Tietz, N.W., ed. Fundamentals of Clinical Chemistry. 3rd. ed. Philadelphia, W.B. saunders: 422 – 447.

Celermajer DS, Sorensen KE, Gooch VM (1992). Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet; 340: 1111–1115.

Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. (2006). Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metabolism; 91:48–53. [PubMed: 16249284]

Enhörning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O (2013). Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective malmö diet and cancer study cardiovascular cohort. Int J Obes (Lond), 37:598–603.

Enhörning S, Struck J, Wirfält E, Hedb lad B, Morgenthaler NG, Melander O (2011). Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab, 96:1065–1072.

Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O (2010). Plasma copeptin and the risk of diabetes mellitus. Circulation, 121:2102–2108.

Enhornling S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O (2013). Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo¨ Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond);37: 598–603.

Escobar-Morreale HF, Luque-Ramirez M, San Millan JL (2005). The molecular genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev, 26:251–282.

Ferriman D, Gallwey JD (1961). Clinical assessment of body hair growth in women. J Clin Endocrinol Metab; 21:1440–7.

Fossati P, Principe L (1982). Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxides. Clinical Chem., 28: 2077 - 2080.

Friedewald, WT, Levy RT, Fredrickson DS (1972). Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem., 18: 499 – 502.

Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C (2008). Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown), 9:987–992.

Gu YL, Voors AA, Zijlstra F, Hillege HL, Struck J, Masson S, Vago T, Anker SD, van den Heuvel AF, van Veldhuisen DJ, de Smet BJ (2011). Comparison of temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction. Clin Res Cardiol, 100:1069–1076.

Holmes CL, Landry DW, Granton JT (2003). Science review: vasopressin and the cardio-vascular system part 1—receptor physiology. Crit care,7:427–434.

Karbek B, Ozbek M, Karakose M, Topaloglu O, Bozkurt NC, Cakır E, Aslan MS, and Delibasi T (2014). Copeptin, a surrogate marker for argininevasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. J Ovarian Res; 7:31.

Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, Roth A, Bickel C, Baldus S, Sinning CR, Wild PS, Lubos E, Peetz D, Kunde J, Hartmann O, Bergmann A, Post F, Lackner KJ, Genth-Zotz S, Nicaud V, Tiret L, Münzel TF, Blankenberg S (2010). Copeptin improves early diagnosis of acute myocardialinfarction. J Am Coll Cardiol, 55:2096–2106.

Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N (2001). Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab, 86:2453–2455.

Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM (2002). Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab, 87:742–746.

Koc¸ M, Kumral ZN, Ozkan N, Memi G, Kaçar Ö, Bilsel S, Çetinel Ş, Yeğen BÇ. (2014). Obestatin improves ischemia/reperfusion-induced renal injury in rats via its antioxidant and anti-apoptotic effects: role of the nitric oxide. Peptides;60C:23–31.

Legro RS (2003). Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev, 24:302–312.

Levy JC, Matthews DR, Hermans MP (1988). Model assessment evaluation uses the computer program. Diabetes Care, 21: 2191 – 2192.

Lopes-Virella, MF, Stone P, Ellis S, Colwell JA (1977). Cholesterol determination in high density lipoproteins separated by three different methods. Clin. Chem., 23: 882.

Macut D, Bjekic´-Macut J, Savic´-Radojevic´ A (2013). Dyslipidemia and oxidative stress in PCOS. Front Horm Res; 40:51–63.

Marcus GJ and Durnford (1985). A simple enzyme-linked immunosorbent assay for testosterone. Steroids. Dec; 46 (6): 975-86.

Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006). Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem, 52:112–119.

Orio F Jr, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, Lombardi G, Colao A (2004). The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case –control study. J Clin Endocrinol Metab, 89:3696–3701.

Pasquali R, Gambineri A, Pagotto U (2006). The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG, 113:1148–1159.

Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R (1986). Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation; 74: 1399–1406.

Porstmann T, Kiessig ST (1992). Enzyme immunoassay techniques. An overview. J Immunol Methods 150: 5-21.

Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, Bergmann A, Potocki M, Noveanu M, Breidthardt T, Christ A, Boldanova T, Merki R, Schaub N, Bingisser R, Christ M, Mueller C (2009). Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol, 54:60–68.

Ren AJ, Guo ZF, Wang YK, Lin L, Zheng X, Yuan WJ (2009). Obestatin,

obesity and diabetes. Peptides; 30:439–44.
Renato Pasquali, Elisabet Stener-Victorin, Bulent O. Yildiz, Antoni J. Duleba, Kathleen Hoeger, Helen Mason, Roy Homburg, Theresa Hickey, Steve Franks, Juha Tapanainen, Adam Balen, David H. Abbott, Evanthia Diamanti-Kandarakis, and Richard S. Legro (2011). PCOS Forum: Research in Polycystic Ovary Syndrome Today and Tomorrow. Clin Endocrinol (Oxf); 74(4): 424–433. doi:10.1111/j.1365-2265.2010.03956. x.
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) (2004). Hum Reprod; 19:41–7.
Ridker PM, Glynn RJ, Hennekens CH (1998). C - reactive protein adds to the predictive value of total and HDL cholesterol in determining the risk of first myocardial infarction. Circulation; 97: 2007-2011
Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr, Kullo IJ. (2009). Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab; 94:2558–64.
Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA (1998). Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J of Clinical Epidemiology.; 51:415–422.
Tang SQ, Jiang QY, Zhang YL, Zhu XT, Shu G, Gao P, Feng DY, Wang XQ, Dong XY (2008). Obestatin: its physicochemical characteristics and physiological functions. Peptides; 29:639–45.
Taskin MI, Bulbul E, Adali E, Hismiogullari AA and Inceboz U (2015). Circulating levels of obestatin and copeptin in obese and non-obese women with polycystic ovary syndrome. European J. Obstetrics and Gynecol. Reprod. Biol. 8938 (2015) 1–5.
Tenderenda-Banasiuk E, Wasilewska A, Filonowicz R, Jakubowska U, Wasz- kiewicz-Stojda M (2014). Serum copeptin levels in adolescents with primary hypertension. Pediatr Nephrol; 29:423–9.
Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K (2009). OPTIMAAL Investigators: C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J, 30:1187–1194.
Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. (1985). Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism.; 61:946–951. [PubMed: 4044782]
Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, Hsueh AJ. (2005). Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310:996-999,
Zhang N, Yuan C, Li Z, Li J, Li X, Li C, Li R, Wang SR (2011). Meta-analysis of the relationship between obestatin and ghrelin levels and the ghrelin/obestatin ratio with respect to obesity. Am J Med Sci; 341:48–55.
Zulfikaroglu E, Islimye M, Tonguc EA, Payasli A, Isman F, Var T, Danisman N. (2011). Circulating levels of copeptin, a novel biomarker in pre-eclampsia. J Obstet Gynaecol Res; 37:1198–202.